Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810833 · ClinicalTrials.gov registry record · NA
Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System
A NA study of Acute Kidney Injury, sponsored by MediBeacon.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03810833 is a NA study of Acute Kidney Injury that has completed, run by MediBeacon. The registered enrollment target is 12 participants, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03810833, a NA study of Acute Kidney Injury, has completed, sponsored by MediBeacon.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate background fluorescence of participants of different ages, gender, and skin color. In addition, 48-hour tolerability of the sensor and adhesive will be evaluated.
Conditions Studied
Interventions
- DEVICE Brilliance device sensor
Study Locations (1)
Missouri
- St. Louis Clinical Trials - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2019-09-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03810833
The ClinicalTrials.gov registry entry for NCT03810833 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The listed sponsor is MediBeacon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which Brilliance device sensor is the first listed.
NCT03810833 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03810833 about?
NCT03810833 is a clinical study titled "Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System". This study is designed to evaluate background fluorescence of participants of different ages, gender, and skin color. In addition, 48-hour tolerability of the sensor and adhesive will be evaluated.
What is the current status of trial NCT03810833?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2019-09-16. Estimated completion is 2019-09-23.
What conditions does trial NCT03810833 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT03810833?
The interventions under investigation include: Brilliance device sensor (DEVICE).
Who is sponsoring clinical trial NCT03810833?
This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03810833 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
-
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
RECRUITING · NA
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
CTSN Embolic Protection Trial
RECRUITING · NA
-
A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention
RECRUITING · NA
-
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.